Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum, and survival

Cancer Research

Volumn 72, Issue 22, 2012, Pages 5675-5682

  Mukhopadhyay, Asima ^a,b   Plummer, Elizabeth R ^b   Elattar, Ahmed ^a,b   Soohoo, San ^a,b   Uzir, Bisha ^b   Quinn, Jennifer E ^c   McCluggage, W Glenn ^d   Maxwell, Perry ^c   Aneke, Harriet ^b   Curtin, Nicola J ^b   Edmondson, Richard J ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PLATINUM COMPLEX; RUCAPARIB;

ADULT; AGED; ARTICLE; ASCITES FLUID; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; EX VIVO STUDY; FEMALE; FOLLOW UP; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNOFLUORESCENCE TEST; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT DURATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; DNA BREAKS, DOUBLE-STRANDED; ENZYME INHIBITORS; FEMALE; HOMOLOGOUS RECOMBINATION; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84869210797     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0324     Document Type: Article

References (39)

1. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
2. Bishop AJ, Schiestl RH. Homologous recombination and its role in carcinogenesis. J Biomed Biotechnol 2002;2:75-85.
3. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-95.
4. David BY, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian cancers. J Clin Oncol 2002;20:463-6.
5. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260-5.
6. Turner N, Tutt A, Ashworth A. Hallmarks of BRCAness in sporadic cancers. Nat Rev Cancer 2004;4:814-9.
7. Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 2010;16:2344-51.
8. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;28:3555-61.
9. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
10. Plummer ER, Calvert H. Targeting poly (ADP-ribose) polymerase: a two armed strategy for cancer therapy. Clin Can Res 2007;13:6252-6.
11. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly (ADP) ribose polymerase in tumours from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
12. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA 1 or BRCA 2 mutations and recurrent ovarian cancer: a proof of concept trial. Lancet 2010;376:245-51.
13. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006;5:135-42.
14. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2010;103:334-46.
15. Karlan BY, Baldwin RL, Lopez-Luevanos E, Raffel LJ, Barbuto D, Narod S, et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 1999;180:917-28.
16. Carser JE, Quinn JE, Michie CO, O'Brien EJ, McCluggage WG, Maxwell P, et al. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol 2011;123:492-8.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours: European Organisation for the Research and Treatment of Cancer, National cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
18. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. Re: New guidelines to evaluate response to treatment in solid tumours (ovarian cancer). J Natl Cancer Inst 2004;96:487-8.
19. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:167-81.
20. Bergmann L, Hirschfeld S, Morris C. Biotherapy Development Association (BDA). Progression free survival as an end point in clinical trials of bio-therapeutic agents. Eur J Cancer 2007;5:23-7.
21. TCGA. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
22. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote IB, Rustin GJS, et al. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). J Clin Oncol 29: 2011 (suppl; abstr 5003).
23. Hennessy B, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, et al. Somatic mutations in BRCA1 and BRCA2 could expend the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010;28:3570-6.
24. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, et al. BRCA1 promoter hypermethylation in ovarian carcinoma: a population based study. Cancer Res 2000;60:5329-33.
25. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002;94:1396-406.
26. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumours. Nat Med 2003;9:568-74.
27. Hughes-Davies L, Hunsman D, Ruas M, Fuks F, Bye J, Chin SF, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003;115:523-35.
28. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA-1 linked, BRCA-2 linked and sporadic ovarian cancers. J Natl Cancer Inst 2002;94:990-1000.
29. Gattipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, et al. Poly (ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 2010;70:5389-98.
30. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;15:2512-9.
31. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15.
32. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005;65:8961-7.
33. Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin CancerRes 2007;13:7413-20.
34. Mendes-Pereira A, Martin S, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN. mutant cells with PARP inhibitors. EMBO Mol Med 2009;1:315-22
35. Sakai W, Swisher EM, Karlan B, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutation as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451:1116-20.
36. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA 1 mutations in BRCA 1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008;68:2581-6.
37. Ang J, Yap TA, Fong PC, Carden PC, Tan DS, Hanwell J, et al. Preliminary experience with the use of chemotherapy following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor in patients with BRCA1/2 deficient ovarian cancer. J Clin Oncol 28:15s, 2010 (suppl; abstr 5041).
38. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
39. Gelmon KA, Hirte HW, Robidoux A, Tonkin KS, Tischkowitz M, Swenerton K, et al. Can we define tumours that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol 28:15s, 2010 (suppl; abstr 3002).